Real-world Multicenter Analysis of Clinical Outcomes and Safety of Meropenem-Vaborbactam in Patients Treated for Serious Gram-Negative Bacterial Infections

被引：40

作者：

Alosaimy, Sara ^{[1
]}

Jorgensen, Sarah C. J. ^{[1
,12
]}

Lagnf, Abdalhamid M. ^{[1
]}

Melvin, Sarah ^{[1
]}

Mynatt, Ryan P. ^{[2
,13
]}

Carlson, Travis J. ^{[3
,14
]}

Garey, Kevin W. ^{[3
]}

Allen, David ^{[4
]}

Venugopalan, Veena ^{[5
]}

Veve, Michael ^{[6
,7
]}

Athans, Vasilios ^{[8
]}

Saw, Stephen ^{[8
]}

Yost, Christine N. ^{[9
]}

Davis, Susan L. ^{[1
,10
]}

Rybak, Michael J. ^{[1
,2
,11
]}

机构：

[1] Wayne State Univ, Dept Pharm Practice, Eugene Applebaum Coll Pharm & Hlth Sci, Antiinfect Res Lab, Detroit, MI USA

[2] Detroit Med Ctr, Dept Pharm Serv, Detroit, MI USA

[3] Univ Houston, Coll Pharm, Houston, TX 77030 USA

[4] Inova Fairfax Med Campus, Dept Pharm, Falls Church, VA USA

[5] Univ Florida, Coll Pharm, Gainesville, FL USA

[6] Univ Tennessee, Coll Pharm, Knoxville, TN USA

[7] Univ Tennessee, Med Ctr, Knoxville, TN USA

[8] Hosp Univ Penn, 3400 Spruce St, Philadelphia, PA 19104 USA

[9] Beaumont Hosp, Royal Oak, MI USA

[10] Henry Ford Hosp, Dept Pharm, Detroit, MI 48202 USA

[11] Wayne State Univ, Sch Med, Dept Med, Div Infect Dis, Detroit, MI 48201 USA

[12] Mt Sinai Hosp, Toronto, ON, Canada

[13] Univ Kentucky Healthcare, Lexington, KY USA

[14] High Point Univ, Fred Wilson Sch Pharm, High Point, NC USA

来源：

OPEN FORUM INFECTIOUS DISEASES | 2020年 / 7卷 / 03期

关键词：

carbapenem-resistant Enterobacteriaceae; Gram-negative infections; meropenem-vaborbactam; multidrug-resistant; SEVERE SEPSIS;

D O I：

10.1093/ofid/ofaa051

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Fourty patients were treated with meropenem-vaborbactam (MEV) for serious Gram-negative bacterial (GNB) infections. Carbapenem-resistant Enterobacteriaceae (CRE) comprised 80.0% of all GNB infections. Clinical success occurred in 70.0% of patients. Mortality and recurrence at 30 days were 7.5% and 12.5%, respectively. One patient experienced a probable rash due to MEV.

引用

页数：4

共 50 条

[41] Real-World Safety and Clinical Outcomes of Macitentan in Asian Patients with Pulmonary Arterial Hypertension: A Prospective Multicenter Study
Jung, Su Young
Chang, Sung-A
Song, Jong-Min
Choi, Jae Young
Kim, Hyung-Kwan
Choi, Jung Hyun
Chin, Jung Yeon
Park, Minseok
Kim, SuYoun
Chang, Hyuk-Jae
[J]. DRUGS-REAL WORLD OUTCOMES, 2023, 10 (01) : 41 - 49
[42] Real-World Safety and Clinical Outcomes of Macitentan in Asian Patients with Pulmonary Arterial Hypertension: A Prospective Multicenter Study
Su Young Jung
Sung-A Chang
Jong-Min Song
Jae Young Choi
Hyung-Kwan Kim
Jung Hyun Choi
Jung Yeon Chin
Minseok Park
SuYoun Kim
Hyuk-Jae Chang
[J]. Drugs - Real World Outcomes, 2023, 10 : 41 - 49
[43] THE INCIDENCE OF GRAM-NEGATIVE BACTERIAL AND FUNGAL-INFECTIONS IN LIVER-TRANSPLANT PATIENTS TREATED WITH SELECTIVE DECONTAMINATION
WIESNER, RH
[J]. INFECTION, 1990, 18 : S19 - S21
[44] CLINICAL OUTCOMES OF PATIENTS IN THE INTENSIVE CARE UNIT WITH INFECTIONS CAUSED BY MULTIRESISTANT GRAM-NEGATIVE BACTERIA IN COLOMBIAN PATIENTS
Varon, F. A.
Silva, E.
Reyes, Sanchez J. M.
Castano, Gamboa N.
Arciniegas, J.
Garcia, M.
[J]. VALUE IN HEALTH, 2024, 27 (06) : S36 - S36
[45] Activity of ceftolozane-tazobactam, ceftazidime-avibactam, meropenem-vaborbactam, cefiderocol and comparators against Gram-negative organisms causing bloodstream infections in Northern Italy (2019-2021): emergence of complex resistance phenotypes
Bianco, Gabriele
Boattini, Matteo
Comini, Sara
Iannaccone, Marco
Casale, Roberto
Allizond, Valeria
Barbui, Anna Maria
Banche, Giuliana
Cavallo, Rossana
Costa, Cristina
[J]. JOURNAL OF CHEMOTHERAPY, 2022, 34 (05) : 302 - 310
[46] Antibiotic strategies and clinical outcomes for patients with carbapenem-resistant Gram-negative bacterial bloodstream infection
Qu, Junyan
Feng, Chunlu
Li, Huan
Lv, Xiaoju
[J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2021, 57 (03)
[47] Efficacy and Safety of Meropenem-Vaborbactam Versus Best Available Therapy for the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Patients Without Prior Antimicrobial Failure: A Post Hoc Analysis
Bassetti, Matteo
Giacobbe, Daniele Roberto
Patel, Niki
Tillotson, Glenn
Massey, Jill
[J]. ADVANCES IN THERAPY, 2019, 36 (07) : 1771 - 1777
[48] Prognostic outcomes and safety in patients treated with pembrolizumab for advanced urothelial carcinoma: experience in real-world clinical practice
Daichi Tamura
Noriaki Jinnouchi
Masakazu Abe
Daiki Ikarashi
Tomohiko Matsuura
Renpei Kato
Shigekatsu Maekawa
Yoichiro Kato
Mitsugu Kanehira
Ryo Takata
Wataru Obara
[J]. International Journal of Clinical Oncology, 2020, 25 : 899 - 905
[49] Prognostic outcomes and safety in patients treated with pembrolizumab for advanced urothelial carcinoma: experience in real-world clinical practice
Tamura, Daichi
Jinnouchi, Noriaki
Abe, Masakazu
Ikarashi, Daiki
Matsuura, Tomohiko
Kato, Renpei
Maekawa, Shigekatsu
Kato, Yoichiro
Kanehira, Mitsugu
Takata, Ryo
Obara, Wataru
[J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (05) : 899 - 905
[50] Real-world clinical outcomes with avelumab in patients with Merkel cell carcinoma treated in the USA: a multicenter chart review study
Bhatia, Shailender
Nghiem, Paul
Veeranki, S. Phani
Vanegas, Alejandro
Lachance, Kristina
Tachiki, Lisa
Chiu, Kevin
Boller, Emily
Bharmal, Murtuza
[J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (08)

← 1 2 3 4 5 →